Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MF59 Adjuvant Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

NCT00973349
View directory record Official record
Conditions
Influenza
Interventions
MF59-eH1N1_f
Biological
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
2,719 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

NCT03682120
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 31, 2026, 2:41 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
View directory record Official record
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
1,500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

NCT01942265
View directory record Official record
Conditions
Influenza
Interventions
AS03, MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
5
States / cities
Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

NCT01423825
View directory record Official record
Conditions
HIV Infections
Interventions
Sub C gp140 Vaccine, MF59C.1 Adjuvant, Sodium chloride
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

NCT03497845
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype
Interventions
VN, IN, dk/BANG, gf/WA, bhg/QL, AS03 adjuvant, MF59 adjuvant
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 49 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
San Diego, California • Peoria, Illinois • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Recombinant CMV gB Vaccine in Postpartum Women

NCT00125502
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
CMV gB vaccine, MF59 adjuvant, Placebo
Biological · Drug
Lead sponsor
Robert Pass, MD
Other
Eligibility
14 Years to 40 Years · Female only
Enrollment
464 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

NCT00001042
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl, Syntex adjuvant formulation, MF59, Threonyl Muramyl Dipeptide, rgp120/HIV-1 SF-2, MTP-PE/MF59
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1996
U.S. locations
3
States / cities
St Louis, Missouri • Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

NCT01162122
View directory record Official record
Conditions
Influenza
Interventions
MF59 adjuvanted trivalent subunit influenza vaccine (aTIV), Non-adjuvanted trivalent subunit influenza vaccine (TIV)
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
65 Years and older
Enrollment
7,109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
Phoenix, Arizona • DeLand, Florida • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

NCT00812019
View directory record Official record
Conditions
Influenza
Interventions
Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years to 40 Years
Enrollment
753 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

NCT00000972
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
MTP-PE/MF59, Env 2-3
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1992
U.S. locations
3
States / cities
Rochester, New York • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 2:41 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

B-19 Parvovirus Vaccine Study

NCT00379938
View directory record Official record
Conditions
Parvovirus B19 Infection
Interventions
VAI-VP705 (parvovirus B-19 vaccine), Placebo, MF-59
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

NCT02213354
View directory record Official record
Conditions
Avian Influenza
Interventions
MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 99 Years
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

NCT05664334
View directory record Official record
Conditions
Healthy
Interventions
IVX-121, IVX-241, Placebo, MF59®
Biological · Other
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

NCT00133497
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
MF-59, Placebo, CMV gB vaccine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 17 Years · Female only
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
5
States / cities
Cincinnati, Ohio • Nashville, Tennessee • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)

NCT00972816
View directory record Official record
Conditions
Influenza
Interventions
MF59-eH1N1
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
3 Years to 8 Years
Enrollment
1,357 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
34
States / cities
Downey, California • Madera, California • Paramount, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

NCT04576702
View directory record Official record
Conditions
Influenza, Human
Interventions
Investigational aIIV4c, IIV4c, aIIV4, RIV4
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
471 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
21
States / cities
Mobile, Alabama • Tempe, Arizona • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults

NCT02624219
View directory record Official record
Conditions
Avian Influenza, Influenza
Interventions
AS03, MF59 adjuvant, Monovalent Influenza A/H5N8 vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Panblok H7 Vaccine Adjuvanted With AS03 or MF59

NCT03283319
View directory record Official record
Conditions
Influenza, Human
Interventions
3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7, MF59, AS03
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 49 Years
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Lenexa, Kansas • Wichita, Kansas • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

NCT05875961
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Mix and Match With MF59

NCT01317745
View directory record Official record
Conditions
Influenza
Interventions
Phosphate Buffered Saline (PBS) diluent, MF59 Adjuvant, H5N1 Antigen
Other · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults

NCT00133471
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H9N2 vaccine, MF59 adjuvant
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 34 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

NCT02915016
View directory record Official record
Conditions
HIV Infections
Interventions
DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 31, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

NCT06015282
View directory record Official record
Conditions
Influenza, Human
Interventions
Investigational aQIVc, licensed QIVr, licensed aQIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
7,741 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
51
States / cities
Tempe, Arizona • Little Rock, Arkansas • Huntington Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 31, 2026, 2:41 PM EDT